Holen Sie sich die Stockscreener-App
2.06
7.62%
-0.17
Handel nachbörslich:
2.06
Schlusskurs vom Vortag:
$2.23
Offen:
$2.27
24-Stunden-Volumen:
1.52M
Relative Volume:
1.61
Marktkapitalisierung:
$87.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.92M
KGV:
-1.20
EPS:
-1.7167
Netto-Cashflow:
$-26.53M
1W Leistung:
+6.19%
1M Leistung:
+18.39%
6M Leistung:
-58.13%
1J Leistung:
+4.04%
1-Tages-Spanne:
$2.05
$2.33
1-Wochen-Bereich:
$1.75
$2.385
52-Wochen-Spanne:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.06 | 94.87M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio regains NYSE listing compliance By Investing.com - Investing.com Australia
Biotech Annovis keeps NYSE listing after falling below $50M thresholds - Stock Titan
Annovis launches proposed public stock and warrant offering - MSN
Annovis Bio Analyst Ratings and Price Targets | NYSE:ANVS - Benzinga
ANVS Technical Analysis | Trend, Signals & Chart Patterns | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Bio director Michael Hoffman buys $142,778 in shares By Investing.com - Investing.com South Africa
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com UK
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Director Michael Hoffman adds 76,344 Annovis Bio (ANVS) shares in open-market buys - Stock Titan
Annovis Bio prices $15 million public offering at $1.90 - Investing.com UK
Annovis Bio Announces Dilutive Equity Offering for Trials - TipRanks
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity - TradingView
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Annovis Bio (NYSE: ANVS) raises $13.8M via 7.895M-share offering and warrants - Stock Titan
Annovis Bio Prices $15 Million Public Offering to Fund Neurodegenerative Disease Trials - MEXC
Annovis Bio slips after pricing $15M equity offering - MSN
Annovis announces pricing of $15.0 million public offering of common stock and accompanying warrants - marketscreener.com
Annovis Bio prices $15 million public offering at $1.90 By Investing.com - Investing.com South Africa
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - The Manila Times
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Biotech Annovis prices $15M offer to fund Alzheimer’s, Parkinson’s studies - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall - Moomoo
Annovis Bio stock tumbles on public offering announcement By Investing.com - Investing.com Nigeria
Annovis Bio (ANVS) registers equity units with detachable warrants in shelf supplement - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Annovis Bio stock tumbles on public offering announcement - Investing.com
Annovis Bio announces public offering of stock and warrants By Investing.com - Investing.com Australia
Annovis Bio announces public offering of stock and warrants - Investing.com
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants - The Manila Times
Biotech Annovis plans stock-and-warrant sale for Alzheimer’s Phase 3 study - Stock Titan
Annovis Bio, Inc. Common Stock (NY: ANVS - The Chronicle-Journal
Annovis Bio, Inc. 1Q 2026: Net income $(17.61M), EPS $(0.63) — 10-Q Summary - TradingView
Rising R&D and going-concern risk at Annovis Bio (ANVS) as cash falls - Stock Titan
Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Annovis Bio Releases Q1 2026 Financial Results - AlphaStreet
Annovis Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - The Manila Times
Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - Moomoo
ANVS Stock Price, Quote & Chart | ANNOVIS BIO (NYSE:ANVS) - ChartMill
TradingKey - TradingKey
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
ANVS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer’s at Fierce Biotech Week - MEXC Exchange
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):